FIG 1.

Antifungal susceptibility pattern of C. auris clinical isolates from New York, 2016 to 2020. (A) Percent C. auris resistant isolates to antifungals for which CDC tentative MIC breakpoint (CDC-BP) are available. Most of the isolates were resistant to fluconazole (FLC) followed by amphotericin B (AMB), with a small number exhibiting resistance to echinocandins. (B) Percent C. auris non-wild-type isolates based on epidemiological cutoff values (ECV). A higher percentage of C. auris isolates were non-wild-type to posaconazole (POS) compared with the other azoles and 5-flucytosine (5-FC).